

Versartis Investor Relations Department 4200 Bohannon Drive Suite 250 Menlo Park, CA 94025 United States

Visit IR website ☐ Sign-up for Email alerts ☐

# NASDAQ: VSAR Last Trade: 2.58 Trade Time: 2:31 PM ET Oct 18, 2017 Change: -0.03 ♣ (-0.962%) Day Range 2.55 - 2.60 52-Week Range 2.35 - 24.00 Volume 628,821

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.


# **Company Profile**

Versartis, Inc.
(NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone to treat growth hormone deficiency (GHD) in children and adults.

Somavaratan is intended to reduce the injection burden of daily therapy and improve therapeutic outcomes through enhanced adherence and convenience with twicemonthly dosing, a fine gauge needle autoinjector device and room temperature storage.

Versartis is currently evaluating somavaratan for the treatment of pediatric ... (more)

# **Stock Performance**



## Press Releases [View all]

Sep 21, 2017

Versartis Announces Phase 3 VELOCITY
Trial of Somavaratan in Pediatric Growth
Hormone Deficiency Did Not Meet Primary
Endpoint

Sep 7, 2017

Versartis' Twice-Monthly Somavaratan for
Pediatric Growth Hormone Deficiency to be
Featured in Oral and Poster Presentations at
IMPE 2017

Sep 5, 2017

Versartis Announces Expansion of Executive
Leadership Team with Addition of Dr.
Robert Gut as the Head of Global Clinical,
Medical and Regulatory Affairs

Aug 2, 2017

<u>Versartis to Present at the Canaccord</u> Genuity Growth Conference

Jul 27, 2017

<u>Versartis Reports Second Quarter 2017</u> Financial Results

## Financials [View all]

Second Quarter Financial Results

Mar 10, 2017

Annual Report (10-K)

Aug 14, 2017 Proxy Statement (DEF 14A)

Aug 7, 2017

Quarterly Report (10-Q)

May 10, 2017

Quarterly Report (10-Q)

Nov 4, 2016

Quarterly Report (10-Q)